Manish Jain

About

Manish Jain, Ph.D., is a Ramalingaswami Fellow at University Institute of Pharmaceutical Sciences, Panjab University, India. He earned his Ph.D. in 2015 from CSIR-Central Drug Research Institute, affiliated to Integral University, India. After getting his Ph.D., Dr. Jain gained postdoctoral research experience at University of Fribourg (Switzerland) and University of Iowa, USA. During his research career, he unfolded several molecular mechanisms that regulate smooth muscle cell proliferation and neo-intimal hyperplasia. He is particularly interested in translational research for the prevention, diagnosis and treatment of cardio-metabolic vascular diseases. He received ATVB Travel Award for Young Investigators to present his work during ATVB/PVD 2018 Scientific Sessions in San Francisco, California. He was also awarded with Senior Research Fellowship from Indian Council of Medical Research to pursue his Ph.D.

Employment

• Panjab University Assistant Professor (Ramalingaswami Fellow)
  2021 - Present
• The University of Iowa
  2017 - 2021
• University of Fribourg Postdoc
  2014 - 2016
• Hygia Institute of Pharmaceuticals Education and Research Assistant Professor
  2013 - 2014
• Lakshmi Narain College of Technology Lecturar
  2006 - 2007

Education

• Central Drug Research Institute Ph.D
  2007 - 2013

Projects & Funding

Projects & funding information is unavailable.

Publications (53)

• Targeting PDK4 attenuates neointimal hyperplasia and regulates VSMC phenotypic switching, apoptosis, and autophagy
  Biochemical Pharmacology 2026 DOI: 10.1016/j.bcp.2026.117805
  +Save
• Design, Synthesis, Biological Evaluation, and In Silico Study of N ‐(Pyrazin‐2‐yl)Alkyl/Aryl Amide Derivatives as Quorum Sensing Inhibitors Against Pseudomonas aeruginosa
  Chemistry & Biodiversity 2026 DOI: 10.1002/cbdv.202502287
  +Save
• TRIM24 Impediment suppresses VSMC modulation and attenuates neointimal hyperplasia via redox and autophagy pathways
  Molecular Biology Reports 2026 DOI: 10.1007/s11033-026-12470-x
  +Save
• Targeting glutaminase C, a splice variant of glutaminase 1, suppresses smooth muscle cell phenotypic modulation and neointimal hyperplasia
  Experimental Cell Research 2025 DOI: 10.1016/j.yexcr.2025.114777
  +Save
• Nanotechnology and artificial intelligence in cancer treatment
  Next Research 2025 DOI: 10.1016/j.nexres.2025.100179
  +Save
• Doxophylline, a Non-Selective Phosphodiesterase Inhibitor, Protects Against Chronic Fatigue-Induced Neurobehavioral, Biochemical, and Mitochondrial Alterations
  Neurochemical Research 2025 DOI: 10.1007/s11064-024-04295-6
  +Save
• Toxicological evaluation of imidazo-based heterocyclic derivatives: In-vitro and in-vivo acute toxicity studies
  Toxicology Reports 2025 DOI: 10.1016/j.toxrep.2024.101872
  +Save
• Exploring Astrocytes Involvement and Glutamate Induced Neuroinflammation in Chlorpyrifos-Induced Paradigm Of Autism Spectrum Disorders (ASD)
  Neurochemical Research 2024 DOI: 10.1007/s11064-024-04191-z
  +Save
• Gamut of glycolytic enzymes in vascular smooth muscle cell proliferation: Implications for vascular proliferative diseases
  Biochimica Et Biophysica Acta Molecular Basis of Disease 2024 DOI: 10.1016/j.bbadis.2024.167021
  +Save
• Synthesis, Evaluation and Docking Studies of Disubstituted N-Heterocyclic Derivatives as Anticancer Agents
  Chemistry and Biodiversity 2024 DOI: 10.1002/cbdv.202401010
  +Save